- Compliant with all federal and state laws; meets new and existing standards implemented by multiple societies.
- The only FDA approved ophthalmic formulation of MMC.
- Integral Closed-System Transfer Device (CSTD) .
- No patient specific, advanced prescription required.
Free Educational Resource
USP <800> Hazardous Drugs:
Handling in Ophthalmic Healthcare Settings.
The Mitosol Kit – Professionally Convenient
Mitosol delivers the first system for MMC designed for use in ophthalmic surgery. On-demand reconstitution eliminates refrigeration and light shielding. Shelf life of up to 24 months. Sterile transfer to the surgical field is compliant with AORN standards. Closed system transfer and qualified disposal strictly minimizes exposure to patients, providers, and allied health personnel.
Convenience: “Shelf-Ready” Convenience for Ophthalmic MMC
Mitosol delivers a turnkey system for preparation, use, and disposal. Reconstituted on-demand, Mitosol does not require refrigeration or light shielding. Shelf life of up to 24 months delivers confidence in meeting your needs and the needs of your patients every time.
- Shelf life of up to 24 months.
- Turnkey system: Preparation, use, delivery, and disposal.
- Room temperature storage – No refrigeration.
- Ambient light storage.
- No patient specific, advance prescription required.
- Eliminates cancellations or rescheduling due to outdated or absent MMC.
- Pre-cut sponges speeds preparation and eliminates scissor cut fragments.
- Reduces OR, staff, and physician downtime.
- Eliminates rushed preparation for last-minute cases.
Mitosol delivers a containment solution crafted specifically for the unique requirements of ophthalmic surgery. Routine atmospheric exposure of a NIOSH recognized HD is eliminated. A patented preparation and delivery system with qualified containment and disposal strictly minimizes exposure to patients, providers and staff.
Mitosol Delivers Strictly Minimized Risk of Exposure
Mitomycin is a NIOSH-recognized HD
- MMC is cytotoxic, cytogenic, mutagenic, and carcinogenic. Demonstrable hazards – contact, vapor, aerosol, etc. – exist in all forms, whether liquid, frozen, or powder.
- Exposure hazards range from temporary rashes to lifelong complications.
- Standards established by ASHP, NIOSH, U.S. Pharmacopeia, and others call for the use of Closed-System Transfer Devices (CSTDs) and personal protective equipment when handling HDs.
Liquid mitomycin-c degrades immediately and continuously. Unless reconstituted at the time of use, actual delivered potency is unknown. Mitosol delivers. On-demand reconstitution delivers consistent potency to every patient, every time.
Mitosol Delivers Consistency
- 0.1% – Hourly degradation rate of liquid MMC.
- 25% – Potential loss of potency from compounding to BUD.
- 100% – Certainty that Mitosol® delivers consistent potency to every patient.
Mitosol Delivers Reduced Variables and Consistent Control
Mitosol is shelf-ready and ALWAYS at time zero. Reconstituted on the sterile field at the time of use, Mitosol delivers control of potency to you and your patients.
By design, Mitosol delivers compliance with the Drug Quality and Security Act providing confidence in your source of supply. Mitosol is FDA approved with an ophthalmic indication. An integral closed system transfer device prevents hazardous exposure. Mitosol delivers your facility compliance with all laws and standards related to the acquisition and use of ophthalmic mitomycin-c.
Sticker prices may differ, but Mitosol delivers superior value. With zero wasted product, and elimination of cancelled procedures due to expired product, Mitosol emerges as the most cost-effective system.
Mitosol Delivers Cost Effectiveness
What is the total cost of…
- Canceled or delayed cases due to lack of MMC availability?
- Wasted inventory due to canceled cases or product expiration?
- Wasted surgeon, staff and OR time?
- Compliance or safety infractions?
WMI-002 Rev 02/2021